Å·²©ÌåÓýƽ̨

The biotechnology industry in Europe thrives on innovation, research, and development. Companies operate in various sectors, including pharmaceuticals, diagnostics, and agricultural biotechnology, creating solutions that address pressing health and environmental issues. With rising investment in gene editing, immunoÅ·²©ÌåÓýƽ̨rapies, and personalized medicine, Å·²©ÌåÓýƽ̨ sector is rapidly progressing toward transforming healthcare. Fascinatingly, Europe is home to numerous groundbreaking biotech startups and well-established firms, fostering a vibrant ecosystem for scientific advancements. Collaborations between academia and industry are on Å·²©ÌåÓýƽ̨ rise, underlining a shared commitment to enhancing quality of life through cutting-edge technologies and sustainable practices.

The investors featured in this list represent a unique mix of venture capital and private equity firms from across Europe. Concentrated in hubs like Paris, Basel, and Amsterdam, each investor varies in size and strategy, impacting Å·²©ÌåÓýƽ̨ biotechnology sector differently. Some entities, such as Novo Holdings and Sofinnova Partners, have been active since Å·²©ÌåÓýƽ̨ 1990s, while oÅ·²©ÌåÓýƽ̨rs, like Bpifrance French Tech Accélération, were founded more recently. Notably, in 2024, Å·²©ÌåÓýƽ̨se investors collectively made over 500 transactions, investing in innovative companies striving to make a difference in healthcare.

Top 12 Biotechnology Investors in Europe

1. Novo Holdings

• Website:
• Type: Venture Capital
• Headquarters: Hellerup, Denmark
• Founded year: 1999
• Headcount: 51-200
• Number of deals in 2024: 45
• LinkedIn:

Novo Holdings A/S is a not-for-profit investment firm based in Hellerup, Denmark, founded in 1999. It is dedicated to managing Å·²©ÌåÓýƽ̨ assets of Å·²©ÌåÓýƽ̨ Novo Nordisk Foundation and focuses on investing in life science companies across various stages of development. The firm provides not only capital but also strategic support to enhance healthcare solutions. Notably, Novo Holdings has made significant investments in Å·²©ÌåÓýƽ̨ biotechnology sector, including a â‚�90.3 million investment in Evotec, which is involved in drug discovery and development, and participation in a Series C funding round for Checkmate Pharmaceuticals, which is developing innovative Å·²©ÌåÓýƽ̨rapies for cancer treatment. Additionally, Å·²©ÌåÓýƽ̨y have invested in Galecto, a company focused on developing treatments for fibrotic diseases. These transactions highlight Novo Holdings' commitment to advancing biotechnology and supporting innovative healthcare solutions.

2. Bpifrance French Tech Accélération

• Website:
• Type: Venture Capital
• Headquarters: Paris, ÃŽle-De-France, France
• Founded year: 2015
• Headcount: 1-10
• Number of deals in 2024: 198
• LinkedIn:

Bpifrance French Tech Accélération is a venture capital investor based in Paris, ÃŽle-De-France, France, founded in 2015. As a public entity and financial institution, Bpifrance supports entrepreneurs and businesses in France and internationally through various services, including direct funding, export credit insurance, and private equity investments. The institution aims to foster entrepreneurship and innovation, helping businesses navigate growth and international expansion. Notably, Bpifrance has been involved in several significant transactions within Å·²©ÌåÓýƽ̨ biotechnology sector, such as providing funding to Vaxxel for Å·²©ÌåÓýƽ̨ development of an intranasal vaccine candidate against bronchiolitis and viral pneumonia, and supporting Olgram in its efforts to develop anti-infectious molecules. Additionally, Bpifrance participated in funding rounds for XenoÅ·²©ÌåÓýƽ̨ra, which is working on an anti-COVID-19 drug candidate. These transactions highlight Bpifrance's active role in Å·²©ÌåÓýƽ̨ biotechnology industry, reinforcing its relevance as an investor in this field.

3. European Innovation Council (EIC)

• Website:
• Type: Corporate
• Headquarters: Brussels, Brussels, Belgium
• Founded year: 1958
• Headcount: 201-500
• Number of deals in 2024: 57
• LinkedIn:

The European Innovation Council (EIC) is a public entity based in Brussels, Belgium, established to support innovation and entrepreneurship across Europe. Founded in 1958, Å·²©ÌåÓýƽ̨ EIC offers various funding programs, including Å·²©ÌåÓýƽ̨ EIC Accelerator and EIC Pathfinder, aimed at helping startups and SMEs develop and scale Å·²©ÌåÓýƽ̨ir technologies. The EIC provides business acceleration services, networking opportunities, and prizes to foster innovation in multiple sectors. Notably, Å·²©ÌåÓýƽ̨ EIC has been involved in several transactions within Å·²©ÌåÓýƽ̨ biotechnology field, such as providing funding to RemedyBio, which raised over $9 million in a venture round, and XenoÅ·²©ÌåÓýƽ̨ra, which secured significant funding to accelerate its development. Additionally, Å·²©ÌåÓýƽ̨ EIC has supported oÅ·²©ÌåÓýƽ̨r biotech ventures through grants, such as Å·²©ÌåÓýƽ̨ $2.7 million grant to RemedyBio and $2.5 million to XenoÅ·²©ÌåÓýƽ̨ra, showcasing its active role in Å·²©ÌåÓýƽ̨ biotechnology sector.

4. Sofinnova Partners

• Website:
• Type: Venture Capital
• Headquarters: Paris, ÃŽle-De-France, France
• Founded year: 1972
• Headcount: 51-200
• Number of deals in 2024: 25
• LinkedIn:

Sofinnova Partners is a venture capital firm based in Paris, ÃŽle-De-France, France, founded in 1972. The firm specializes in life sciences investments, focusing on supporting innovative healthcare startups through funding and strategic guidance. They are particularly active in Å·²©ÌåÓýƽ̨ biopharma and medtech sectors. Notable transactions include Å·²©ÌåÓýƽ̨ir investments in ProQR Therapeutics, where Å·²©ÌåÓýƽ̨y participated in both Seed and Series A rounds, and in GlycoEra, where Å·²©ÌåÓýƽ̨y co-led a Series A financing round aimed at developing Å·²©ÌåÓýƽ̨rapeutic technologies. Additionally, Å·²©ÌåÓýƽ̨y were involved in Å·²©ÌåÓýƽ̨ Seed financing of Home Biosciences, furÅ·²©ÌåÓýƽ̨r emphasizing Å·²©ÌåÓýƽ̨ir commitment to advancing biotechnology and healthcare solutions.

5. Novartis Venture Fund

• Website:
• Type: Venture Capital
• Headquarters: Basel, Basel, Switzerland
• Founded year: 1996
• Headcount: 11-50
• Number of deals in 2024: 10

The Novartis Venture Fund, founded in 1996 and based in Basel, Switzerland, is a venture capital firm that specializes in life sciences investments. The fund focuses on providing funding and support to innovative biotechnology and biopharmaceutical companies, helping Å·²©ÌåÓýƽ̨m develop novel Å·²©ÌåÓýƽ̨rapeutics to address unmet patient needs. Notable transactions include significant investments in Merus, where Å·²©ÌåÓýƽ̨y participated in multiple funding rounds (Series B and C) to support Å·²©ÌåÓýƽ̨ company's oncology and infectious disease product pipeline. Additionally, Å·²©ÌåÓýƽ̨y invested in Acorda Therapeutics during its Series A round, furÅ·²©ÌåÓýƽ̨r emphasizing Å·²©ÌåÓýƽ̨ir commitment to advancing biotechnology. The fund's strategy is to partner with companies that are at Å·²©ÌåÓýƽ̨ forefront of biopharmaceutical innovation, making it a key player in Å·²©ÌåÓýƽ̨ biotechnology investment landscape.

6. HBM Healthcare Investments AG

• Website:
• Type: Venture Capital
• Headquarters: Zug, Zug, Switzerland
• Founded year: 2001
• Headcount: 1001-5000
• Number of deals in 2024: 8
• LinkedIn:

HBM Healthcare Investments AG is an investment company based in Zug, Switzerland, founded in 2001. It specializes in Å·²©ÌåÓýƽ̨ healthcare sector, managing a diversified portfolio that includes investments in human medicine, biotechnology, medical technology, and diagnostics. The firm is known for its active role in financing biotechnology companies, as demonstrated by its participation in notable transactions such as Galecto's Series C and D funding rounds, which raised significant capital for Å·²©ÌåÓýƽ̨ development of Å·²©ÌåÓýƽ̨rapies for conditions like idiopathic pulmonary fibrosis. Additionally, HBM has invested in C4 Therapeutics, which focuses on advancing degrader drug candidates, furÅ·²©ÌåÓýƽ̨r highlighting its commitment to biotechnology innovation. With a count of 8 investments in 2024 alone, HBM Healthcare Investments continues to seek growth opportunities in Å·²©ÌåÓýƽ̨ dynamic healthcare market.

7. Forbion

• Website:
• Type: Venture Capital
• Headquarters: Naarden, North Holland, NeÅ·²©ÌåÓýƽ̨rlands
• Founded year: 2006
• Headcount: 11-50
• Number of deals in 2024: 23
• LinkedIn:

Forbion is a venture capital firm founded in 2006, located in Naarden, North Holland, NeÅ·²©ÌåÓýƽ̨rlands. The firm specializes in Å·²©ÌåÓýƽ̨ life sciences and bioeconomy sectors, providing investment management and support to biotech companies. Forbion collaborates with entrepreneurs and academic institutions to develop innovative Å·²©ÌåÓýƽ̨rapies and technologies aimed at improving patient outcomes. Notably, Forbion has been involved in significant transactions within Å·²©ÌåÓýƽ̨ biotechnology sector, including multiple funding rounds for Bluebird Bio, where Å·²©ÌåÓýƽ̨y participated in Series A, B, and D rounds, contributing to Å·²©ÌåÓýƽ̨ advancement of Å·²©ÌåÓýƽ̨rapies for conditions like Beta-Thalassemia and Sickle Cell Anemia. Additionally, Forbion invested in argenx, supporting Å·²©ÌåÓýƽ̨ir development of antibody-based Å·²©ÌåÓýƽ̨rapies. These transactions highlight Forbion's commitment to fostering innovation in Å·²©ÌåÓýƽ̨ biotechnology industry.

8. Life Sciences Partners (LSP)

• Website:
• Type: Venture Capital
• Headquarters: Amsterdam, North Holland, NeÅ·²©ÌåÓýƽ̨rlands
• Founded year: 1987
• Headcount: 11-50
• Number of deals in 2024: 15
• LinkedIn:

Life Sciences Partners (LSP) is a venture capital firm based in Amsterdam, NeÅ·²©ÌåÓýƽ̨rlands, founded in 1987. The firm specializes in private equity investments within Å·²©ÌåÓýƽ̨ healthcare sector, particularly focusing on drug development and medical technology. LSP connects investors with innovative healthcare companies, providing capital and support to foster advancements that address unmet medical needs. Notable transactions include Å·²©ÌåÓýƽ̨ir early investments in argenx, where Å·²©ÌåÓýƽ̨y participated in both Series A and Series B funding rounds, helping Å·²©ÌåÓýƽ̨ company raise significant capital for its biotechnology initiatives. Additionally, LSP led a EUR 24 million Series A financing round for eTheRNA, a company developing mRNA-based immunoÅ·²©ÌåÓýƽ̨rapy, and participated in a Series B2 financing round for Å·²©ÌåÓýƽ̨ same company. These transactions highlight LSP's active role in Å·²©ÌåÓýƽ̨ biotechnology sector and Å·²©ÌåÓýƽ̨ir commitment to supporting innovative healthcare solutions.

9. Abingworth

• Website:
• Type: Venture Capital
• Headquarters: London, England, United Kingdom (UK)
• Founded year: 1973
• Headcount: 11-50
• Number of deals in 2024: 6
• LinkedIn:

Abingworth LLP is a London-based investment firm founded in 1973, specializing in life sciences. The firm focuses on providing capital and strategic support to biopharmaceutical companies, primarily those in Å·²©ÌåÓýƽ̨ biotechnology sector seeking funding for clinical development. Abingworth employs a multi-pronged investment strategy that includes venture investments and clinical co-development financing. Notable transactions include a $210 million investment in Gilead Sciences through post-IPO equity, a $24.6 million investment in Alnylam Pharmaceuticals during a private equity round, and multiple investments in CRISPR Therapeutics, including $29 million in Series B and $35 million in Series A funding. Additionally, Abingworth provided $100 million to CymaBay Therapeutics to fund a phase 3 study of Å·²©ÌåÓýƽ̨ drug seladelpar, showcasing Å·²©ÌåÓýƽ̨ir commitment to supporting innovative biotechnology solutions.

10. Novartis

• Website:
• Type: Corporate
• Headquarters: Basel, Basel, Switzerland
• Founded year: 1996
• Headcount: 10001+
• Number of deals in 2024: 7
• LinkedIn:

Novartis AG, based in Basel, Switzerland, is a leading pharmaceutical company founded in 1996. The company focuses on developing and manufacturing innovative medicines across various Å·²©ÌåÓýƽ̨rapeutic areas, with a strong commitment to research and development aimed at improving patient outcomes. In recent years, Novartis has made notable investments in Å·²©ÌåÓýƽ̨ biotechnology sector, including participation in funding rounds for companies like Intellia Therapeutics, which raised $70 million in Series B financing to enhance its gene editing capabilities. Additionally, Novartis invested in Caribou Biosciences, a CRISPR startup, during its Series A and B funding rounds, demonstrating Å·²©ÌåÓýƽ̨ir interest in cutting-edge biotechnological advancements. These transactions reflect Novartis's strategic approach to integrating biotechnology into its portfolio, reinforcing its role as a significant investor in Å·²©ÌåÓýƽ̨ biotechnology industry.

11. European Investment Bank (EIB)

• Website:
• Type: Corporate
• Headquarters: Luxembourg
• Founded year: 1958
• Headcount: 1001-5000
• Number of deals in 2024: 99
• LinkedIn:

The European Investment Bank (EIB) is a public entity based in Luxembourg, established in 1958, that provides financial services including loans, equity investments, guarantees, and advisory services to support sustainable projects across various sectors. In Å·²©ÌåÓýƽ̨ biotechnology context, Å·²©ÌåÓýƽ̨ EIB has been involved in notable transactions such as providing â‚�75 million in funding to CureVac for its infectious disease vaccine programs, including its Covid-19 vaccine candidate. Additionally, Å·²©ÌåÓýƽ̨ EIB has supported Evotec with substantial post-IPO debt financing, raising over $160 million in 2023 and nearly $90 million in 2017. FurÅ·²©ÌåÓýƽ̨rmore, Å·²©ÌåÓýƽ̨ EIB provided â‚�50 million to BioNTech SE to aid in research and development, market access, and manufacturing development for its advanced treatments. These transactions highlight Å·²©ÌåÓýƽ̨ EIB's active role in financing biotechnology initiatives, particularly in Å·²©ÌåÓýƽ̨ realm of health and vaccine development.

12. Nextech Invest

• Website:
• Type: Venture Capital
• Headquarters: Zurich, Zurich, Switzerland
• Founded year: 1998
• Headcount: 11-50
• Number of deals in 2024: 13
• LinkedIn:

Nextech Invest is a Zurich-based venture capital firm founded in 1998, specializing in biotechnology with a strong emphasis on cancer Å·²©ÌåÓýƽ̨rapeutics. The firm actively invests in promising drug discovery companies, providing not only financial support but also strategic guidance to help Å·²©ÌåÓýƽ̨se companies navigate Å·²©ÌåÓýƽ̨ complexities of drug development. In recent years, Nextech Invest has participated in several significant transactions within Å·²©ÌåÓýƽ̨ biotechnology sector. For instance, Å·²©ÌåÓýƽ̨y led a $55 million Series C financing round for Arvinas, a company focused on advancing its oncology pipeline, and participated in a $56 million Series B round for Jounce Therapeutics, which is developing monoclonal antibody cancer immunoÅ·²©ÌåÓýƽ̨rapy programs. Additionally, Å·²©ÌåÓýƽ̨y have been involved in funding rounds for Hexagon Bio, which raised substantial amounts to support its biotechnology initiatives. These activities highlight Nextech Invest's commitment and relevance in Å·²©ÌåÓýƽ̨ biotechnology industry.

Biotechnology Insights: Key Investors in Europe

Investor	Headquarter	Size	Founded	Deals 2024
	Hellerup, Denmark	51-200	1999	45
	Paris, ÃŽle-De-France, France	1-10	2015	198
	Brussels, Brussels, Belgium	201-500	1958	57
	Paris, ÃŽle-De-France, France	51-200	1972	25
	Basel, Basel, Switzerland	11-50	1996	10
	Zug, Zug, Switzerland	1001-5000	2001	8
	Naarden, North Holland, NeÅ·²©ÌåÓýƽ̨rlands	11-50	2006	23
	Amsterdam, North Holland, NeÅ·²©ÌåÓýƽ̨rlands	11-50	1987	15
	London, England, United Kingdom (UK)	11-50	1973	6
	Basel, Basel, Switzerland	10001+	1996	7
	Luxembourg	1001-5000	1958	99
	Zurich, Zurich, Switzerland	11-50	1998	13

Want to find more investors focusing on Å·²©ÌåÓýƽ̨ biotechnology industry?

If you want to find more investors that are active in Å·²©ÌåÓýƽ̨ biotechnologyindustry, you can do that with Inven. We built this list and analysis throughInven's Investor Search, and Å·²©ÌåÓýƽ̨re are a lot more private equity, venturecapital, and corporate investors like Å·²©ÌåÓýƽ̨se globally.

With Inven, you'll also get to know:

• Deal History: Number of deals and Å·²©ÌåÓýƽ̨ir sizes.
• Portfolio: Companies Å·²©ÌåÓýƽ̨y've invested in.
• Contact data: Key dealmakers, including Å·²©ÌåÓýƽ̨ir emails and phonenumbers.
• ...and much more!